At a charge for biotechnology therapy of $4,000, an extra $60,303 per patient in the CUTI group and extra $64,562 per patient in the NRTI group is required for the additional resolution of major complications over standard therapy alone. At a charge for biotechnology therapy of $2,000, an extra $30,000 (CUTI) and $17,049 (NRTI) per patient is required for the additional resolution of major complications over standard therapy alone. The use of biotechnology over standard therapy alone was always more cost-effective in the NRTI population. For patients with NRTI, biotechnology therapy priced at $2,000 became more cost-effective when the probability of major complications was greater than 0; resolution rate was greater than 0.65; intensive care unit charge per day was more than $662; ward charge per day was more than $0; and charge for major complications per day was more than 0 for adult respiratory distress syndrome or disseminated intravascular coagulation. For patients with CUTI, biotechnology therapy priced at $2,000 became more cost-effective when the probability of major complications was greater than 0.54; resolution rate was greater than 0.41; intensive care unit charge per day was greater than $1,593; ward charge per day was greater than $560; and charge for major complications per day was more than 770 for acute renal failure.